Nanomedical Diagnostics VP Production to Speak at Materials Research Society Spring Meeting

Share Article

Dr. Mitchell Lerner will share details about the fabrication process behind the world’s first mass-manufactured graphene biosensor, AGILE R100.

VP Production Dr. Mitchell Lerner of Nanomedical Diagnostics

Nanomedical Diagnostics VP Production Dr. Mitchell Lerner

Graphene biosensors theoretically could replicate the high-volume, low-cost fabrication process of computers, but no one knew how. We cracked that with AGILE R100.

In the past decade, graphene biosensors have achieved star status in the biomedical field, pushing existing linear detection ranges and sensitivity limits in lab studies. As electronic devices, they are small, easy to operate, and fast, leading biomedical researchers to dream of their use in everything from drug discovery to disease diagnostics to health monitoring. Only one obstacle stood in the way: No one could figure out how to manufacture graphene biosensors at scale…until now. Dr. Mitchell Lerner of Nanomedical Diagnostics will speak at the Materials Research Society (MRS) Spring Meeting in Phoenix, AZ on April 19 to share how the company has broken the mass-manufacturing barrier for graphene biosensors.

“To fabricate graphene biosensors at scale, we had to solve three main problems,” says VP Production Dr. Lerner. “The first is that run-of-the-mill graphene can’t be used for biosensors meant to generate highly-sensitive results. For that kind of exceptional detection, zero-defect graphene is needed, and no one has produced significant volumes of that class of graphene before. The second challenge involves the ability to meld the low-cost world of electronics manufacturing with the groundbreaking material graphene. As an all-electronic product, graphene biosensors theoretically could leverage the high-volume, low-cost fabrication process of computers, but no one knew how. We cracked that with AGILE R100. And the last is rarely discussed. Graphene biosensors will provide current and conductance data, but how is that data translated into results that are relevant for the life science or health application that’s being studied, in a cost-effective, customer-friendly manner? We designed a compact, hand-held reader that connects to the graphene biosensor and outputs automated, real-time analytics pertinent to the customer.”

Nanomedical Diagnostics is a biotech company that is the world’s only provider of graphene biosensor technology, with a mission to transform the healthcare industry with innovative new products that enable cutting-edge life science research, drug discovery applications, and diagnostic and health monitoring platforms. Dr. Lerner, an 11-year veteran of nanomaterials research and production scale up, will be part of the symposium on 2D Materials in the MRS meeting which brings together researchers across disciplines to explore the cutting edge in materials science.

In addition to MRS, Nanomedical Diagnostics will present its graphene biosensor AGILE R100 at the American Association of Pharmaceutical Scientists (AAPS) National Biotechnology Conference in San Diego from May 1 through 3.

AGILE R100 is available for commercial sale, for research use only. For more information, visit http://www.nanomedicaldiagnostics.com.

About Nanomedical Diagnostics

Nanomedical Diagnostics (“Nanomed”) is a biotech company based in San Diego, CA. Nanomed has developed a breakthrough electronic assay based on Field Effect Biosensing (FEB) technology that provides real-time, label-free kinetic binding, affinity, and concentration data. Unique graphene biosensors at the heart of the assay deliver highly-sensitive biophysical characterization of small molecules ≥1 Da in complex media such as DMSO, using unprecedentedly small amounts of sample, making the platform a novel orthogonal option for drug discovery hit validation and lead optimization.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Angela Shue
Visit website